In-situ tumor vaccination: Bringing the fight to the tumor

Robert H. Pierce, Jean S. Campbell, Sara I. Pai, Joshua D. Brody, Holbrook E K Kohrt

Research output: Contribution to journalArticle

Abstract

After decades of development in the shadow of traditional cancer treatment, immunotherapy has come into the spotlight. Treatment of metastatic tumors with monoclonal antibodies to T cell checkpoints like programed cell death 1 (PD-1) or its ligand, (PD-L1), have resulted in significant clinical responses across multiple tumor types. However, these therapies fail in the majority of patients with solid tumors, in particular those who lack PD1+CD8+ tumor-infiltrating lymphocytes within their tumors. Intratumoral “in situvaccination” approaches seek to enhance immunogenicity, generate tumor infiltrating lymophcytes (TIL) and drive a systemic anti-tumor immune response, directed against “unvaccinated,” disseminated tumors. Given the emerging picture of intratumoral immunotherapy as safe and capable of delivering systemic efficacy, it is anticipated that these approaches will become integrated into future multi-modality therapy.

Original languageEnglish (US)
Pages (from-to)1901-1909
Number of pages9
JournalHuman Vaccines and Immunotherapeutics
Volume11
Issue number8
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Vaccination
Neoplasms
Immunotherapy
Tumor-Infiltrating Lymphocytes
Therapeutics
Cell Death
Monoclonal Antibodies
Ligands
T-Lymphocytes

Keywords

  • Adaptive resistance
  • Immunotherapy
  • Intratumoral
  • Melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Pierce, R. H., Campbell, J. S., Pai, S. I., Brody, J. D., & Kohrt, H. E. K. (2015). In-situ tumor vaccination: Bringing the fight to the tumor. Human Vaccines and Immunotherapeutics, 11(8), 1901-1909. https://doi.org/10.1080/21645515.2015.1049779

In-situ tumor vaccination : Bringing the fight to the tumor. / Pierce, Robert H.; Campbell, Jean S.; Pai, Sara I.; Brody, Joshua D.; Kohrt, Holbrook E K.

In: Human Vaccines and Immunotherapeutics, Vol. 11, No. 8, 01.01.2015, p. 1901-1909.

Research output: Contribution to journalArticle

Pierce, RH, Campbell, JS, Pai, SI, Brody, JD & Kohrt, HEK 2015, 'In-situ tumor vaccination: Bringing the fight to the tumor', Human Vaccines and Immunotherapeutics, vol. 11, no. 8, pp. 1901-1909. https://doi.org/10.1080/21645515.2015.1049779
Pierce, Robert H. ; Campbell, Jean S. ; Pai, Sara I. ; Brody, Joshua D. ; Kohrt, Holbrook E K. / In-situ tumor vaccination : Bringing the fight to the tumor. In: Human Vaccines and Immunotherapeutics. 2015 ; Vol. 11, No. 8. pp. 1901-1909.
@article{16ab305d478a4989862e094be8cf8b0d,
title = "In-situ tumor vaccination: Bringing the fight to the tumor",
abstract = "After decades of development in the shadow of traditional cancer treatment, immunotherapy has come into the spotlight. Treatment of metastatic tumors with monoclonal antibodies to T cell checkpoints like programed cell death 1 (PD-1) or its ligand, (PD-L1), have resulted in significant clinical responses across multiple tumor types. However, these therapies fail in the majority of patients with solid tumors, in particular those who lack PD1+CD8+ tumor-infiltrating lymphocytes within their tumors. Intratumoral “in situvaccination” approaches seek to enhance immunogenicity, generate tumor infiltrating lymophcytes (TIL) and drive a systemic anti-tumor immune response, directed against “unvaccinated,” disseminated tumors. Given the emerging picture of intratumoral immunotherapy as safe and capable of delivering systemic efficacy, it is anticipated that these approaches will become integrated into future multi-modality therapy.",
keywords = "Adaptive resistance, Immunotherapy, Intratumoral, Melanoma",
author = "Pierce, {Robert H.} and Campbell, {Jean S.} and Pai, {Sara I.} and Brody, {Joshua D.} and Kohrt, {Holbrook E K}",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/21645515.2015.1049779",
language = "English (US)",
volume = "11",
pages = "1901--1909",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - In-situ tumor vaccination

T2 - Bringing the fight to the tumor

AU - Pierce, Robert H.

AU - Campbell, Jean S.

AU - Pai, Sara I.

AU - Brody, Joshua D.

AU - Kohrt, Holbrook E K

PY - 2015/1/1

Y1 - 2015/1/1

N2 - After decades of development in the shadow of traditional cancer treatment, immunotherapy has come into the spotlight. Treatment of metastatic tumors with monoclonal antibodies to T cell checkpoints like programed cell death 1 (PD-1) or its ligand, (PD-L1), have resulted in significant clinical responses across multiple tumor types. However, these therapies fail in the majority of patients with solid tumors, in particular those who lack PD1+CD8+ tumor-infiltrating lymphocytes within their tumors. Intratumoral “in situvaccination” approaches seek to enhance immunogenicity, generate tumor infiltrating lymophcytes (TIL) and drive a systemic anti-tumor immune response, directed against “unvaccinated,” disseminated tumors. Given the emerging picture of intratumoral immunotherapy as safe and capable of delivering systemic efficacy, it is anticipated that these approaches will become integrated into future multi-modality therapy.

AB - After decades of development in the shadow of traditional cancer treatment, immunotherapy has come into the spotlight. Treatment of metastatic tumors with monoclonal antibodies to T cell checkpoints like programed cell death 1 (PD-1) or its ligand, (PD-L1), have resulted in significant clinical responses across multiple tumor types. However, these therapies fail in the majority of patients with solid tumors, in particular those who lack PD1+CD8+ tumor-infiltrating lymphocytes within their tumors. Intratumoral “in situvaccination” approaches seek to enhance immunogenicity, generate tumor infiltrating lymophcytes (TIL) and drive a systemic anti-tumor immune response, directed against “unvaccinated,” disseminated tumors. Given the emerging picture of intratumoral immunotherapy as safe and capable of delivering systemic efficacy, it is anticipated that these approaches will become integrated into future multi-modality therapy.

KW - Adaptive resistance

KW - Immunotherapy

KW - Intratumoral

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84944450609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944450609&partnerID=8YFLogxK

U2 - 10.1080/21645515.2015.1049779

DO - 10.1080/21645515.2015.1049779

M3 - Article

C2 - 26055074

AN - SCOPUS:84944450609

VL - 11

SP - 1901

EP - 1909

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 8

ER -